Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Symantec, NIO, and Karyopharm Therapeutics Jumped Today

By Dan Caplinger - Jul 3, 2019 at 3:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Markets rose in a shortened pre-holiday trading session.

The stock market gained ground on Wednesday, sending several major indexes to record highs. Investors remain upbeat about the potential for long-term economic growth, with increasing confidence that the Federal Reserve will step in to cut rates in an effort to keep the U.S. economy out of recession. Even in a shortened trading session in advance of the July 4 holiday, several stocks posted substantial gains. Symantec ( NLOK -4.14% ), NIO ( NIO -2.10% ), and Karyopharm Therapeutics ( KPTI -3.74% ) were among the top performers. Here's why they did so well.

Symantec gets buying interest

Shares of Symantec jumped nearly 14% after news surfaced that it might be an acquisition target. Reports late Tuesday suggested that Broadcom was discussing buying out Symantec, and analysts weighed in with their assessment that any potential deal could fetch somewhere between $26 and $28 per share for Symantec investors. That might sound like a big premium, but it's not that much higher than where the cybersecurity specialist's shares traded before its most recent earnings report. Yet with former CEO Greg Clark having stepped down unexpectedly, many see an acquisition as the best way to make the most of Symantec's business opportunities.

Blue sportscar with doors open vertically.

Image source: NIO.

NIO drives higher

NIO saw its stock climb 11% as the Chinese electric vehicle manufacturer rode on the coattails of its U.S. counterpart. Yesterday afternoon, Tesla reported its production and delivery figures for the second quarter, and the numbers reached record levels and indicated extremely strong demand for the company's vehicles. NIO is trying to capture some of the same trends in the Chinese auto market, and investors seem to think that what's good for Tesla should also work for NIO. Even with today's gains, though, NIO has struggled, and its stock is down 70% since March.

Karyopharm gets a thumbs-up

Finally, shares of Karyopharm Therapeutics soared 36%. The cancer-fighting-drug maker announced that its Xpovio treatment for patients with multiple myeloma has received approval from the U.S. Food and Drug Administration. Karyopharm did note that continued approval for the specific indication, which identifies only certain groups of multiple myeloma patients, might be contingent on verification of the clinical benefit from the drug in confirmatory trials. Investors had hoped that an FDA decision to extend the period for approving Xpovio back in March was a positive sign, and as it turns out, their patience got rewarded.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NortonLifeLock Inc. Stock Quote
NortonLifeLock Inc.
$23.82 (-4.14%) $-1.03
Karyopharm Therapeutics Inc. Stock Quote
Karyopharm Therapeutics Inc.
$6.69 (-3.74%) $0.26
NIO Inc. Stock Quote
NIO Inc.
$38.31 (-2.10%) $0.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.